Newsroom | 21961 results

BETHESDA, Md. & GAITHERSBURG, Md.--(BUSINESS WIRE)--Longhorn Vaccines and Diagnostics, a One Health company developing vaccines and diagnostic tools for global public health and zoonosis concerns, presented new data at the World Vaccine Congress 2025 on LHNVD-303, the company's composite peptide vaccine for sepsis due to bacterial infections and its applications in inflammatory diseases. The World Vaccine Congress took place in Washington, D.C. from April 22-24. Sepsis is a life-threatening com...

TORONTO & PHILADELPHIA--(BUSINESS WIRE)--Radiant Biotherapeutics Announces Poster Presentation at 2025 American Association for Cancer Research (AACR) Annual Meeting...

CONCORD, Mass.--(BUSINESS WIRE)--ClearB Therapeutics, Inc., a company developing therapeutic vaccines designed to drive a functional cure for Hepatitis B, announced today that an abstract will be presented as a poster at the European Association for the Study of the Liver (EASL) International Liver Congress (ILC) 2025, taking place in Amsterdam, the Netherlands 7 – 10 May 2025. “We are excited to share preclinical data on our therapeutic vaccine candidate, CLB-4000, with the Hepatitis B communi...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the New England Journal of Medicine (NEJM) has published a detailed analysis of the Phase III CENTERSTONE trial of Xofluza® (baloxavir marboxil). The trial met its primary endpoint, showing a single, oral dose of Xofluza taken by people infected with influenza reduced the odds of untreated household members contracting the virus by 32%. For the key secondary end...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its first quarter 2025 results of operations. “Gilead had a strong start to the year driven by excellent commercial and clinical execution along with disciplined expense management,” said Daniel O’Day, Gilead’s Chairman and Chief Executive Officer. “Our base business grew 4% year-over-year, primarily led by Biktarvy’s continued strength, and we announced positive topline Phase 3 results for Trodelvy plus...

ROCKVILLE, Md.--(BUSINESS WIRE)--BIOQUAL, Inc. www.bioqual.com BIOQ(Pinksheets) BIOQUAL, Inc., announced today that Mr. Michael P. O’Flaherty will retire from his role as a BIOQUAL Board Member effective May 1, 2025. Mr. O’Flaherty served as the Chief Operating Officer and Secretary of the Corporation until he retired in 2015 at which time he was elected to the BIOQUAL Board. Mr. O’Flaherty is 86 years old and has served as a Director since 2015. His retirement is not connected to any disagreem...

METAIRIE, La.--(BUSINESS WIRE)--RestorixHealth, the nation’s leading wound care solutions company, has announced new corporate leadership in Ben Dunford, MBA, as Chief Executive Officer (CEO) and Melinda Estep, MBA, as Chief Financial Officer (CFO). Dunford brings to RestorixHealth a wealth of healthcare experience serving in various c-suite roles, including CFO at Texas Regional Medical Center at Sunnyvale, Chief Operating Officer (COO) at NorthStar Anesthesia, President of Rural Physicians Gr...

MARTIGNY, Svizzera e DIGIONE, Francia--(BUSINESS WIRE)--Debiopharm Research & Manufacturing S.A. (Debiopharm, www.debiopharm.com), un'azienda biofarmaceutica globale con sede in Svizzera che opera nell'ambito della cura del cancro e delle malattie infettive, e Oncodesign Services (www.oncodesign-services.com), una CRO leader specializzata nella scoperta di farmaci e nei servizi preclinici, hanno annunciato la sottoscrizione di un accordo di licenza per l'uso della tecnologia AbYlink™ per i...

MARTIGNY, Zwitserland & DIJON, Frankrijk--(BUSINESS WIRE)--Debiopharm Research & Manufacturing S.A. (Debiopharm, www.debiopharm.com), een internationaal biofarmaceuticabedrijf gevestigd in Zwitserland dat zich tot doel stelt om kanker en besmettelijke ziekten te behandelen, en Oncodesign Services (www.oncodesign-services.com), een toonaangevende CRO gespecialiseerd in het ontdekken van geneesmiddelen en preklinische services, kondigen de uitvoering aan van een licentieakkoord voor het gebru...

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will present data from a 24-week subgroup analysis of its ongoing Phase 2 SOLSTICE trial in chronic hepatitis delta at the upcoming European Association for the Study of the Liver (EASL) Congress 2025 in Amsterdam (The Netherlands), May 7-10. The Company will also present 24 Week post-treatment follow-up data from the MARCH Phase 2 clinical study evaluating combinations of tobevibart and elebsiran,...